• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Youth, Antidepressant Medications, and Type 2 Diabetes

Youth, Antidepressant Medications, and Type 2 Diabetes

May 1, 2018
Adam Strassberg, MD.
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Adam Strassberg, MD. Dr. Strassberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Burco M et al, JAMA Pediatrics 2017;171(12):1200–1207

Over the last decade, several published studies have reported an increased risk of type 2 diabetes associated with antidepressant use in adults. But does the same hold true for children and adolescents?

This paper is the first population-based study to examine the risk of onset of type 2 diabetes with the use of antidepressants in younger patients.

Medicaid administrative claims data from California, Florida, Illinois, and New Jersey were analyzed in a cohort of 119,608 youths, ages 5–20, who initiated treatment with antidepressants from 2005 through 2009. Regression models were used to analyze the risk of onset of type 2 diabetes relative to antidepressant use, duration, and dosing.

Current use of antidepressants was associated with a 1.92 adjusted relative risk for type 2 diabetes (95% CI, 1.43–2.57). Current users of SSRIs or SNRIs had a 1.88 adjusted relative risk (95% CI 1.34–2.64), and current users of TCAs had a 2.15 adjusted relative risk (95% CI 1.06–4.36). There were no elevated risks in current users of antidepressants other than SSRIs, SNRIs, or TCAs.

For SSRIs or SNRIs, the risk of onset of type 2 diabetes increased with longer durations of exposure and with larger cumulative dosing. Compared to risk for their use for the first 90 days, there was a relative risk of 1.68 (CI 0.83–3.40) for 91–150 days of use, 2.56 (CI 1.29–5.08) for 151–210 days of use, and 2.66 (CI 1.45–4.88) for > 210 days of use.

Compared to risk after a cumulative antidepressant dose of 1 mg–1500 mg of fluoxetine hydrochloride equivalents, there is a relative risk of 1.22 (CI 0.59–2.52) for 1501 mg–3000 mg of dose equivalents, 2.17 (1.07–4.40) for 3001–4500 mg of dose equivalents, and 2.44 (1.35–4.43) for > 4500 mg of dose equivalents.

CCPR’s Take
The study suggests that long-term antidepressant use, particularly with SSRIs or SNRIs, is associated with increased risk of onset of type 2 diabetes mellitus in children and adolescents. This increased risk is particularly prominent with long-term use and higher daily doses. But the study is observational and must be interpreted with caution. Causality cannot be inferred; however, there is a correlation. Type 2 diabetes mellitus represents a rare but serious adverse outcome to discuss with patients and families, and we should vigilantly monitor for it.
Child Psychiatry
KEYWORDS antidepressants child-psychiatry psychopharmacology_tips
    Adam Strassberg, MD.

    Can Mindfulness-Based Stress Reduction Affect Symptom Outcomes in Older Adults?

    More from this author
    www.thecarlatreport.com
    Issue Date: May 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Psychotropic Risks in Children and Adolescents, CCPR, May/June 2018
    Informed Consent: An Ongoing Process for Focused Care
    Embracing Conflict in the Consent Process
    Considerations When Prescribing Psychotropic Medications
    Metformin to Control Antipsychotic-Induced Weight Gain in Children
    Tips for Good Medication Practice
    Youth, Antidepressant Medications, and Type 2 Diabetes
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.